Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04602221 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04602221 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 40 participants.
The verdict
NCT04602221, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809 and lamotrigine attenuate ketamine induced cognitive deficits.
Interventions
- DRUG Placebo
- DRUG Lamotrigine
- DRUG BI 409306
- DRUG BI 425809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2022-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04602221
The ClinicalTrials.gov registry entry for NCT04602221 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04602221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04602221 about?
NCT04602221 is a clinical study titled "A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine". The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809 and lamotrigine attenuate ketamine induced cognitive deficits.
What is the current status of trial NCT04602221?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-12-01. Estimated completion is 2022-08-12.
What interventions are being tested in trial NCT04602221?
The interventions under investigation include: Placebo (DRUG), Lamotrigine (DRUG), BI 409306 (DRUG), BI 425809 (DRUG).
Who is sponsoring clinical trial NCT04602221?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.